3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
8
Neoplasms
2
Colonic Neoplasms
2
Rectal Neoplasms
1
Prostatic Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Female Breast Carcinoma
1
Female Breast Cancer
1
Interventions
Early Intervention, Educational
5
Radiotherapy
4
Psychiatric Rehabilitation
4
Capecitabine
4
pembrolizumab
3
Trastuzumab
3
Methods
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Gemcitabine
3
Counseling
3
trametinib
2
palbociclib
2
cediranib
2
Standard of Care
2
Mental Status and Dementia Tests
2
Fluorodeoxyglucose F18
2
Docetaxel
2
Cyclophosphamide
2
Biopsy
2
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
2
veliparib
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
tipifarnib
1
spartalizumab
1
sargramostim
1
sapanisertib
1
relatlimab
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
Sevoflurane
×
Breast
×
Clear all
NCT01975064
2022-12-14
CAN
Uppsala University
Phase 4
Completed
5,774 enrolled